Renibus Therapeutics Strengthens IP Position with Additional US Patent SOUTHLAKE, Texas, April 13, 2022 (GLOBE NEWSWIRE) -- Renibus Therapeutics® (“Renibus”), a clinical-stage biotech company focusing on the prevention and treatment of cardio-renal diseases, today...

Renibus Therapeutics Announces Publication of Positive Results of RBT-3 Experimental Preclinical Studies in Scientific Journal Nephrology Dialysis Transplant -With no currently approved therapies for the prevention or treatment of platinum-induced toxicity, RBT-3 has the potential to fill a critical unmet medical need Dallas, Texas, Feb. 16, 2021 ...